Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/6c3125d8bb8a96020322ccb69ad3322af3301835" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Merck, Moderna Melanoma Vaccine Study Succeeds"></iframe>